NCT04644770 2026-03-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
Clinical Trials
19 trialsNCT04943536 2026-02-27
BiolenRT
Alessa Therapeutics Inc.
Phase 1 Active not recruiting
NCT03924869 2025-12-11
KEYNOTE-867
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT04365374 2025-10-07
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies, Inc.
Phase 3 Active not recruiting
NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
NCT03169790 2025-02-24
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03167164 2025-02-21
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03167177 2025-02-21
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03169738 2025-02-21
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03169777 2025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03197571 2025-02-21
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT01539824 2024-11-25
A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer
Immodulon Therapeutics Ltd
Phase 2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT03340974 2023-12-15
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
Galera Therapeutics, Inc.
Phase 1/2 Completed
NCT00643617 2023-05-09
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Accuray Incorporated
Phase NA Completed
NCT00643994 2023-05-09
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
Accuray Incorporated
Phase NA Completed
NCT02721056 2021-05-10
NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers
Nanobiotix
Phase 1/2 Terminated
NCT00643318 2021-03-05
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
Accuray Incorporated
Phase 2 Unknown
NCT01973608 2016-10-31
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
EMD Serono
Phase 2 Terminated